SCHEMBL9865577

SCHEMBL9865577

Cc1ccc(O)c(=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 1/20 0.56
MMP2 P08253 1/20 0.48
DBH P09172 1/20 0.48
TRPA1 O75762 1/20 0.48
ACHE P22303 2/20 0.48
TDP1 Q9NUW8 3/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MAPK1 P28482 1/20 0.46
TP53 P04637 2/20 0.46
CSNK2A1 P68400 1/20 0.43
ALDH1A1 P00352 3/20 0.42
ALOX15 P16050 3/20 0.42
HSD17B10 Q99714 2/20 0.42
MCL1 Q07820 1/20 0.42
LMNA P02545 3/20 0.42
CES2 O00748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21471512 0.93 MCL1 (0.52) TYRMMP2DBHTRPA1ACHE
SCHEMBL30894892 0.82 TYR (0.50) TYRMMP2DBHTRPA1ACHE
SCHEMBL10339603 0.77 TYR (0.54) TYRMMP2DBHACHETDP1
SCHEMBL14425214 0.72 TYR (0.50) TYRMMP2DBHTDP1MEN1
SCHEMBL21465807 0.72 TYR (0.50) TYRMMP2DBHTDP1MEN1
SCHEMBL23250747 0.72 TYR (0.50) TYRMMP2DBHTDP1MEN1
SCHEMBL11193755 0.72 TYR (0.56) TYRMMP2DBHTDP1MEN1
SCHEMBL916337 0.72 TYR (0.56) TYRMMP2DBHTDP1MEN1
SCHEMBL23250710 0.72 HDAC4 (0.56) TYRTDP1MEN1MAPTKMT2A
SCHEMBL6212439 0.72 HDAC4 (0.55) TYRMMP2DBHTDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
WO-2021076945-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 WO disclosed
US-9790158-B2 Substituted tropolone derivatives and methods of use UNIVERSITY OF CONNECTICUT (US) 2017-10-17 US disclosed
US-20150166448-A1 Substituted Tropolone Derivatives and Methods of Use UNIVERSITY OF CONNECTICUT 2015-06-18 US disclosed
EP-1116769-B1 Electrolyte composition, electrochemical cell and ionic liquid crystal monomer FUJIFILM CORP (JP) 2011-12-14 EP disclosed
WO-2007101882-A1 TROPOLONE- AND HYDROXYBENZENE-SUBSTITUTED OLIGOPEPTIDES FOR DEPIGMENTATION BEIERSDORF AG (DE) 2007-09-13 WO disclosed
US-7259187-B2 Tropolone derivatives RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2007-08-21 US disclosed
US-7259187-B2 Tropolone derivatives RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2007-08-21 US disclosed
US-20070185055-A1 Method for treating cachexia with retinoid ligands JIANG GUANG LIANG 2007-08-09 US disclosed
US-5003077-A Having a cycloheptimidazole nucleus; photostability; methine bond having an auxochrome FUJI PHOTO FILM CO., LTD. (JP) 1991-03-26 US disclosed
US-4900648-A RECORDING, ERASING USING LASER BEAM, METHINE DYE FUJI PHOTO FILM CO., LTD. (JP) 1990-02-13 US disclosed
US-4814265-A CONTAINING METHANE DYE FUJI PHOTO FILM CO., LTD. (JP) 1989-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166448-A1 Substituted Tropolone Derivatives and Methods of Use HDAC5, HDAC4, HDAC7 TYR 1992/4885MMP2 680/4885DBH 891/4885
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TXNRD1, SDHB TYR 512/4885MMP2 4478/4885DBH 122/4885
US-20070185055-A1 Method for treating cachexia with retinoid ligands RXRA, RXRG, RXRB TYR 4435/4885MMP2 3894/4885DBH 2108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.